SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is facing intense volatility as traders react to the cyclical nature of its heavy concentration in South Korean semiconductor giants like Samsung and SK Hynix. The community is actively debating whether the stock's recent aggressive price swings represent a sustainable bull cycle fueled by AI-driven memory chip shortages or a risky, over-leveraged trade prone to rapid technical corrections.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

The ProShares Bitcoin Strategy ETF is trending as investors grapple with its ongoing price volatility alongside broader market fluctuations in Bitcoin. Community discussion is heavily focused on the contrast between the ETF's consistent monthly dividend payouts and the NAV decay, with many debating whether to hold for income or shift into spot Bitcoin products.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is facing intense volatility following a critical security audit that uncovered a long-standing bug in its privacy protocol, sparking a massive sell-off as traders scramble to evaluate the risk of potential counterfeit supply. While developers have already deployed a patch, the community remains deeply polarized between those panic-selling over transparency concerns and others viewing the significant price dip as a rare buying opportunity for a hardened network.

Telesat Corp. engages in the provision of satellite communications and consulting services. It operates through Geostationary (GEO) and Low Earth Orbit (LEO) segments. It is a global satellite operator, providing mission-critical communications solutions to support the requirements of sophisticated satellite users throughout the world and consists of 14 geostationary satellites and the Canadian payload on Viasat-1. The company was founded in 1969 and is headquartered in Ottawa, Canada.

Telesat Corp - Ordinary Shares - Class A

Telesat is generating significant investor buzz following the successful finalization of multibillion-dollar government funding agreements, which are set to accelerate the development of its Lightspeed satellite constellation. The community is actively discussing the potential for a long-term rerating as the company transitions from legacy operations to a next-generation LEO network while navigating heavy short interest and speculative volatility.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as investors react to reports of a potential multibillion-dollar equity offering aimed at funding massive AI infrastructure investments. The community remains deeply divided, with some viewing the potential dilution as a necessary step to stay competitive in the AI arms race, while others criticize the spending as wasteful and express frustration over the stock's inability to sustain upward momentum.

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals is currently capturing investor attention following a strategic deal with Apotex and ongoing clinical momentum for its pipeline drug, ifetroban. The community is actively discussing the stock's tight float, potential squeeze dynamics, and the high-value implications of upcoming ifetroban data for Duchenne muscular dystrophy and oncology indications.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Constellation Energy Corp

Constellation Energy is experiencing significant volatility as investors weigh the stock's role as a primary nuclear power provider for AI data centers against near-term regulatory concerns and earnings guidance that trailed analyst expectations. While the community remains focused on the structural necessity of nuclear power for scaling AI infrastructure, active discussions are currently split between capitalizing on the stock's recent dip as a long-term value opportunity and hedging against potential grid-related policy risks.

Solidion Technology, Inc. engages in researching, developing and manufacturing battery components and materials, batteries and related energy storage products for the automotive electric vehicle and other markets. The company was founded on June 30, 2023 and is headquartered in Dallas, TX.

Solidion Technology Inc

Solidion Technology Inc. is seeing intense investor interest driven by back-to-back announcements regarding proprietary lithium-metal battery patents, which are being linked by the community to high-growth themes like space infrastructure, SpaceX's upcoming IPO, and AI-driven energy needs. While bullish sentiment focuses on extreme short-squeeze potential and a low float, others are debating whether the rapid valuation jump is backed by fundamental commercial progress or speculative hype.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone Inc. is trending as the private credit sector faces heightened scrutiny and liquidity concerns, highlighted by rising investor redemption requests across flagship funds. The community is actively debating the stability of the private credit market and whether recent price volatility offers a strategic entry point for this major alternative asset manager.

ETF Opportunities Trust - T-Rex 2X Inverse MSTR Daily Target ETF

T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ is seeing high engagement from traders capitalizing on increased volatility in MicroStrategy, with the community actively debating whether the stock's inverse leverage offers a sustainable path for profit or carries significant decay risks. Investors are heavily focused on navigating the ongoing price swings by using technical setups to scale in and out of positions while monitoring Bitcoin's broader market trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Astellas Pharma (ALPMY) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?

Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.

Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?

Ocugen faces cash burn and dilution risks, but upcoming eye gene therapy data and planned filings through 2027 could shape its next phase.

MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer

Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.

Are Medical Stocks Lagging  Astellas Pharma (ALPMY) This Year?

Here is how Astellas Pharma Inc. (ALPMY) and BillionToOne (BLLN) have performed compared to their sector so far this year.

Are Medical Stocks Lagging  Arcellx (ACLX) This Year?

Here is how Arcellx, Inc. (ACLX) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.

Here is how Astellas Pharma Inc. (ALPMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.

Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?

Here is how Astellas Pharma Inc. (ALPMY) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Japan’s Astellas Pharma hits 8-mth high on upbeat Q1 earnings

Investing.com-- Shares of  Astellas Pharma Inc.  (TYO:4503) jumped to an eight-month high on Thursday after the Japanese drugmaker reported robust first-quarter earnings, driven by strong sales of key cancer treatments and cost-cutting measures.

Are Medical Stocks Lagging  Abbott Laboratories (ABT) This Year?

Here is how Abbott (ABT) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products: XTANDI, PADCEV, XOSPATA, VYLOY, VEOZAH, IZERVAY, EVRENZO, BETANIS and PROGRAF. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.31	--	--	N/A
Q4 '25	$0.19	$0.15	-21.56%	MISSED
Q3 '25	$0.29	$0.36	22.53%	BEAT
Q2 '25	$0.20	$0.29	44.05%	BEAT
Q1 '25	$0.14	$0.25	87.25%	BEAT

ALPMYASTELLAS PHARMA/ADR

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest ALPMY News